Travere Therapeutics, Inc.
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$66.17
Price-1.99%
-$1.34
1Y
Price
Market Cap
$6.153b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-19.4%
EBITDA Margin-20.5%
Net Profit Margin+34.2%
Free Cash Flow Margin-19.4%
EBITDA Margin-20.5%
Net Profit Margin+34.2%
Free Cash Flow MarginRevenue
$591.331m
+20.5%
1y CAGR+63.8%
3y CAGR+56.1%
5y CAGREarnings
-$43.464m
-70.1%
1y CAGR-55.6%
3y CAGR-26.7%
5y CAGREPS
-$0.49
+12.5%
1y CAGR-24.4%
3y CAGR-1.9%
5y CAGRBook Value
$24.522m
$799.360m
Assets$774.838m
Liabilities$616.905m
DebtDebt to Assets
77.2%
399.5x
Debt to EBITDAFree Cash Flow
$51.518m
+352.9%
1y CAGR+147.2%
3y CAGR+97.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company